Spire Wealth Management Boosts Stake in Humana Inc. (NYSE:HUM)

Spire Wealth Management increased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 21,908.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,923 shares of the insurance provider's stock after buying an additional 7,887 shares during the quarter. Spire Wealth Management's holdings in Humana were worth $2,096,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Lecap Asset Management Ltd. purchased a new stake in shares of Humana during the first quarter worth $3,923,000. YHB Investment Advisors Inc. bought a new stake in shares of Humana in the first quarter worth about $609,000. Asset Management One Co. Ltd. grew its stake in shares of Humana by 5.3% in the first quarter. Asset Management One Co. Ltd. now owns 56,473 shares of the insurance provider's stock worth $14,943,000 after purchasing an additional 2,829 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in Humana by 197.8% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 9,835 shares of the insurance provider's stock valued at $2,602,000 after acquiring an additional 6,533 shares in the last quarter. Finally, Continuum Advisory LLC lifted its holdings in shares of Humana by 2.6% during the first quarter. Continuum Advisory LLC now owns 14,571 shares of the insurance provider's stock valued at $3,855,000 after purchasing an additional 369 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM stock traded up $1.92 during mid-day trading on Friday, hitting $241.82. The company had a trading volume of 1,755,323 shares, compared to its average volume of 1,817,394. The company has a 50-day moving average price of $242.39 and a 200 day moving average price of $259.73. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $29.18 billion, a price-to-earnings ratio of 17.10, a P/E/G ratio of 1.80 and a beta of 0.43. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business's revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company earned $7.23 EPS. On average, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.46%. Humana's dividend payout ratio is currently 25.04%.

Analysts Set New Price Targets

HUM has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Barclays set a $268.00 price objective on shares of Humana and gave the company an "equal weight" rating in a research report on Thursday, June 12th. Robert W. Baird boosted their price objective on shares of Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, April 15th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $280.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.